Clinical Trial Update: Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting [Phase 2]

View source ↗

Summary

VAL-083 (dianhydrogalactitol) is being studied in MGMT unmethylated, bevacizumab-naive glioblastoma patients in the adjuvant or recurrent setting in a Phase 2 t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioma

Drugs mentioned

• VAL-083 (dianhydrogalactitol)

Snippet

Sponsor: Kintara Therapeutics, Inc. | Conditions: Glioma, Glioblastoma | Phase 2 | Status: COMPLETED